Baird Reiterates Neutral Rating on Amgen (AMGN)

Baird analyst Brian Skorney reiterated a Neutral rating and $173.00 price target on Amgen (NASDAQ: AMGN)

The analyst comments "Amgen's updated KRAS lung cancer data continue to look good, although compared to the super-high expectations set by the ASCO data, there is likely some letdown as response rates look modestly worse and durability wasn't fantastic. However, it's rare to see anything like a single-agent ORR of around 50% in a relapsed lung cancer setting."

For an analyst ratings summary and ratings history on Amgen click here. For more ratings news on Amgen click here.

Shares of Amgen closed at $199.00 yesterday.

You May Also Be Interested In

• Amgen (AMGN) PT Raised to $388 at Guggenheim
• Fiserv (FISV) PT Lowered to $60 at Freedom Broker
• KinderCare Learning Companies (KLC) PT Lowered to $4.50 at UBS